Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

Lung Cancer

Volumn 111, Issue , 2017, Pages 61-64

  Ou, Sai Hong Ignatius ^a   Horn, Leora ^b   Cruz, Marcelo ^c   Vafai, Davood ^d   Lovly, Christine M ^b   Spradlin, Allison ^e   Williamson, Michael J ^e   Dagogo Jack, Ibiayi ^f   Johnson, Adrienne ^g   Miller, Vincent A ^g   Gadgeel, Shirish ^h   Ali, Siraj M ^g   Schrock, Alexa B ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Centro Oncologico Antonio Ermirio de Morares Coaem Hospital   (Brazil)

^d EISENHOWER MEDICAL CENTER   (United States)

^e BALL MEMORIAL HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g FOUNDATION MEDICINE   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CHLOROPLAST DNA; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 3 TACC3 FUSION PROTEIN; GEMCITABINE; HYBRID PROTEIN; NAQUOTINIB; NIVOLUMAB; ONCOPROTEIN; OSIMERTINIB; PACLITAXEL; PEMETREXED; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; UNCLASSIFIED DRUG; VINORELBINE TARTRATE; Y163C PROTEIN; ANTINEOPLASTIC AGENT; CIRCULATING TUMOR DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE INHIBITOR; TACC3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; DNA ISOLATION; DRUG WITHDRAWAL; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; TUMOR CELL LINE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CIRCULATING TUMOR DNA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 85024503517     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.07.006     Document Type: Article

References (15)

1. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3(March (75)), 2011 75ra26.
2. Yu, H.A., Arcila, M.E., Rekhtman, N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
3. Thress, K.S., Paweletz, C.P., Felip, E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
4. Yu, H.A., Tian, S.K., Drilon, A.E., et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 1 (2015), 982–984.
5. Ou, S.H., Agarwal, N., Ali, S.M., High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer 98 (2016), 59–61.
6. Chabon, J.J., Simmons, A.D., Lovejoy, A.F., et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun., 7(June), 2016, 11815.
7. Klempner, S.J., Bazhenova, L.A., Braiteh, F.S., et al. Emergence of RET rearrangement co- existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer 89 (2015), 357–359.
8. Allen, J.M., Schrock, A.B., Erlich, R.L., et al. Genomic profiling of circulating tumor DNA in relapsed EGFR-mutated lung adenocarcinoma reveals an acquired FGFR3-TACC3 fusion. Clin. Lung Cancer 22:December (16) (2016), 30382–30385 pii: S1525-7304.
9. Liang, W., He, Q., Chen, Y., et al. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report. BMC Cancer, 16(February (62)), 2016, 12.
10. Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
11. Ou, S.I., Young, L., Schrock, A.B., et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 12 (2017), 137–140.
12. Kim, Y., Hammerman, P.S., Kim, J., et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J. Clin. Oncol. 32 (2014), 121–128.
13. Wang, R., Wang, L., Li, Y., et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin. Cancer Res. 20 (2014), 4107–4114.
14. Capelletti, M., Dodge, M.E., Ercan, D., et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin. Cancer Res. 20 (2014), 6551–6558.
15. Daly, C., Castanaro, C., Zhang, W., et al. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene 36 (2017), 471–481.